Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Australia / NCT05650866
Active, not recruiting Not applicable

Safety and Tolerability of a Novel Implantable Device for the Treatment of Erectile Dysfunction

NCT05650866 · tracked via the Priya Life Science Australia tracker
Sponsor
Comphya Australia
Phase
Not applicable
Started
2023-05-19
Last updated
2026-09-25

Condition(s) studied

Erectile Dysfunction Following Radical Prostatectomy

Investigational drug(s) / intervention(s)

Activation of pro-erectile nerves within the pelvic plexus

Activation of pro-erectile nerves within the pelvic plexus: The study device is an active implantable device. The device activates the cavernous nerves by delivering electrical pulses, to trigger an on-demand erection. The daily delivery of electrical pulses to the cavernous nerves will also allow participants to recover natural erectile function.

Study summary

The goal of this clinical trial is to assess if a new device is safe to use as a potential treatment for erectile dysfunction following radical prostatectomy.

The main questions it aims to answer are:

* Is the device safe?
* Does the device works well? Are the participants satisfied with the device?

Participants will be implanted with the device during the ongoing prostatectomy surgery and will be asked to complete the following tasks during 6 months follow-up:

* Come to the hospital for follow-up visits,
* Complete questionnaires,
* Activate the device every day,
* Measure erection hardness.

Researchers will compare an implanted group (participants having the device) with a control group (participants not having the device) to see if the device works well.

Eligibility

Sex
MALE
Min age
30 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria: * Men of ages between 30-70 years; * Men with indication for nerve-sparing prostatectomy surgery; * Localised prostate cancer considered suitable for bilateral nerve sparing prostatectomy according to clinical criteria * International Index of Erectile Function (IIEF-15) erectile function domain score equal to or greater than 26 prior prostatectomy; * Men interested in minimizing the effect of radical prostatectomy on erectile function; * Ability to read and understand patient information materials and willingness to sign a written informed consent. Exclusion Criteria: * Men with neurological disease, including a history of spinal cord injury or trauma; * IIEF-15 erectile function domain score less than 26 prior prostatectomy; * Failure to demonstrate adequate nocturnal erectile function prior prostatectomy; * History of erectile dysfunction, priapism and Peyronie disease; * History of previous pelvic surgery, trauma or irradiation therapy; * Currently have an active implantable device; * Patient diagnosed with neurologic degenerative diseases that may negatively impact erectile functions; * Identification of technical or clinical limitation to properly apply the use of nerve-sparing techniques during operation; * Inability to understand and demonstrate device use instructions; * Patients with insulin-dependent diabetes who suffer peripheral neuropathy or other diabetes associated complications; * Patient unwillingness to engage in sexual activity; * Patient is currently participating in another clinical investigation that would serve as a contraindication to implant a neurostimulator device to augment erectile function; * Have participated in any drug or device trial in the last 4 weeks or plan to participate in any other drug or device study during the next 24 months; * Possess any other characteristics that, per the investigator's judgment, may increase the risk or impair data collection for the procedure/study; * Patient is a member of a vulnerable population (Vulnerable participants include those who lack consent capacity, including the mentally ill, prisoners, cognitively impaired participants, and employee volunteers).

Primary outcome measure(s)

  • Occurrence of adverse events — 6 months
    Adverse events will be reported using MedDRA terminology.
  • Occurrence of surgical complications — 6 months
    Surgical complications will be ranked according to the Clavien-Dindo classification
  • Occurrence of device deficiencies — 6 months
    Device deficiencies will be systematically reported and recorded.
  • Pain — 6 months
    Patients will be asked to rate pain on a visual analog scale (from 0 to 10)

Trial sites (4)

FacilityCityRegionStatus
St. Vincent's Private Hospital Fitzroy Victoria
Royal Melbourne Hospital Melbourne Victoria
Australian Prostate Centre North Melbourne Victoria
Epworth HealthCare Richmond Victoria

Other trials for the same condition

Multimodal Prehabilitation and Rehabilitation for Men Undergoing Robot-Assisted Radical Prostatectomy Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05650866 on ClinicalTrials.gov ↗ ← All trials in Australia